Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

被引：0
|
作者：
Kiver, Verena [1 ]
Hamilton, Erika [2 ]
Tsurutani, Junji [3 ]
Curigliano, Giuseppe [4 ]
Martin, Miguel [5 ]
O'sullivan, Ciara [6 ]
Sohn, Joo Hyuk [7 ]
Tryfonidis, Konstantinos [8 ]
Santarpia, Libero [9 ]
Yang, Shan [9 ]
Dieras, Veronique [10 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[6] Mayo Clin, Rochester, MN USA
[7] Yonsei Canc Ctr, Seoul, South Korea
[8] Merck & Co Inc, Rahway, NJ USA
[9] Seagen Inc, Bothell, WA USA
[10] Eugene Marquis Ctr, Rennes, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [1] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Mueller, V
    Hamilton, E.
    Tsurutani, J.
    Curigliano, G.
    Martin, M.
    O'Sullivan, C.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 173 - 173
  • [2] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Hamilton, Erika
    Tsurutani, Junji
    Sohn, Joohyuk
    Curigliano, Giuseppe
    O'Sullivan, Ciara C.
    Martin, Miguel
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2023, 83 (08)
  • [3] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Hamilton, Erika
    Tsurutani, Junji
    Curigliano, Giuseppe
    Martin, Miguel
    O'Sullivan, Ciara C.
    Sohn, Joo Hyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress).
    Hamilton, Erika P.
    Maria O'Sullivan, Ciara Catherine
    Martin, Miguel
    Sohn, Joohyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress)
    Hamilton, Erika
    Tsurutani, Junji
    Curigliano, Giuseppe
    Martin, Miguel
    O'Sullivan, Ciara
    Sohn, Joo Hyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Dieras, V. C.
    Martin Jimenez, M.
    O'Sullivan, C. C. M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2022, 33 : S222 - S222
  • [7] HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer
    Hamilton, Erika P.
    Martin, Miguel
    O'Sullivan, Ciara Catherine
    Curigliano, Giuseppe
    Sohn, Joohyuk
    Tsurutani, Junji
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Phase 3 study of maintenance treatment of tucatinib or placebo in combination with trastuzumab and pertuzumab in HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Muller, V
    Hamilton, E.
    O 'Sullivan, C.
    Martin, M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [9] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
    Park-Simon, T. -W
    Okines, A.
    Paplomata, E.
    Wahl, T.
    Wright, G.
    Sutherland, S.
    Jakobsen, E.
    Valdes-Albini, F.
    Chan, A.
    Clark, A. S.
    Conlin, A.
    Lustberg, M.
    Specht, J.
    Pluard, T.
    Zhu, X.
    Krop, I
    Gelmon, K.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 243 - 244
  • [10] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
    Okines, Alicia Frances Clare
    Paplomata, Elisavet
    Wahl, Tanya A.
    Wright, Gail Lynn Shaw
    Sutherland, Stephanie
    Jakobsen, Erik
    Valdes, Frances
    Chan, Arlene
    Clark, Amy Sanders
    Conlin, Alison Katherine
    Lustberg, Maryam B.
    Specht, Jennifer M.
    Pluard, Timothy J.
    Zhu, Xiaofu
    Krop, Ian E.
    Gelmon, Karen A.
    Slamon, Dennis J.
    Ramos, Jorge
    An, Grace
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345